Portal de Periódicos da CAPES

Experience with historical control studies in cancer immunotherapy

1984; Wiley; Volume: 3; Issue: 4 Linguagem: Inglês

10.1002/sim.4780030406

1097-0258

Carl Pinsky,

Immunotherapy and Immune Responses

Statistics in MedicineVolume 3, Issue 4 p. 325-329 Article Experience with historical control studies in cancer immunotherapy Carl M. Pinsky, Carl M. Pinsky Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, U.S.A.Search for more papers by this author Carl M. Pinsky, Carl M. Pinsky Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, U.S.A.Search for more papers by this author First published: October/December 1984 https://doi.org/10.1002/sim.4780030406Citations: 10AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Old, L. J., Clarke, D. A. and Benacerraf, S. ‘Effect of Bacillus Calmette-Guerin infection of transplanted tumors in the mouse’, Nature, 18, 291– 292 (1959). 2 Mathe, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlomberger, J. R., Hayat, M. and de Vassal, F. ‘Active immunotherapy for acute lymphoblastic leukemia’, Lancet, i, 697– 699 (1969). 3 Andrien, J. M., Beumer-Jockmans, M. P., Bury, J., David, J. L., Delalieux, G., Delbeke, M. J., Denolin, R., De Porre, P., Fiere, D., Flowerdew, G., George, S. L., Hainaut, H., Hugues, J., Kenis, Y., Masure, R., Maurus, R., Michel, J., Otten, J., Peetermans, M. E., Reginster-Bous, M., Stryckmans, P. A., Sylvester, R., Van Glabbeke, M., Van Hove, W., Verbist, L., Wennerholm, A. and Williart, H. ‘ Immunotherapy versus chemotherapy as maintenance treatment of acute lymphoblastic leukemia’, in W. D. Terry and D. Windhorst (eds), Immunotherapy of Cancer: Present Status of Trials in Man, Raven Press, New York, 1978, pp. 471– 480. 4 Kay, H. E. M. ‘ Acute lymphoblastic leukemia: 5-year follow-up of the Concord Trial’, in W. D. Terry and D. Windhorst (eds), Immunotherapy of Cancer: Present Status of Trials in Man, Raven Press, New York, 1978, pp. 493– 496. 5 Gutterman, J. U., Hersh, E. M., Rodriguez, V., McCredie, K. B., Mavligit, G., Reed, R., Burgess, M. A., Smith, T., Gehan, E. A., Bodey, G. P. Sr. and Freireich, E. J. ‘Chemoimmunotherapy of adult acute leukemia: prolongation of remission in myeloblastic leukemia with BCG’, Lancet, ii, 1405– 1409 (1974). 6 Hewlett, J. S., Balcerzak, S., Gutterman, J. U., Freireich, E. J., Gehan, E. A. and Kennedy, A. ‘ Remission duration in adult acute leukemia with and without BCG: A Southwest Oncology Group Study’, in W. D. Terry and D. Windhorst (eds), Immunotherapy of Cancer: Present Status of Trials in Man, Raven Press, New York, 1978, pp. 383– 390. 7 Fahey, J. and others. Discussion in W. D. Terry and D. Windhorst (eds), Immunotherapy of Cancer: Present Status of Trials in Man, Raven Press, New York, 1978, pp. 431– 440. 8 Vogler, W. R., Winton, E. F., Gordon, D. S., Jarrell, R., Lefante, J. and Hearn, E. ‘ A Phase III trial comparing BCG alone, cytosine arabinoside plus daunorubicin, and a combination of BCG, cytosine arabinoside, and daunorubicin for maintenance therapy in acute myelogenous leukemia’, in W. D. Terry and S. A. Rosenberg (eds), Immunotherapy of Human Cancer, Elsevier North Holland, New York, Amsterdam, Oxford, 1982, pp. 7– 10. 9 Morton, D. L., Eilber, F. R., Malmgren, R. A. and Wood, W. C. ‘Immunological factors which influence response to immunotherapy in malignant melanoma’, Surgery, 68, 158– 164 (1970). 10 Pinsky, C. M., Hirshaut, Y. and Oettgen, H. F. ‘Treatment of malignant melanoma by intralesional injection of BCG’, National Cancer Institute Monograph, 39, 225– 228 (1973). 11 Gutterman, J. U., Mavligit, G. M., McBride, C. M., Frei, E. III, Freireich, E. J. and Hersh, E. M. ‘Active immunotherapy with BCG for recurrent malignant melanoma’, Lancet, i, 1208– 1212 (1973). 12 Morton, D. L., Eilber, F. R., Holmes, E. C., Hunt, J. S., Ketcham, A. S., Silverstein, M. J. and Sparks, F. C. ‘BCG immunotherapy of malignant melanoma: summary of a seven year experience’, Annals of Surgery, 180, 635– 643 (1974). 13 Morton, D. L., Holmes, E. C., Eilber, F. R. and Ramming, K. P. ‘ Adjuvant immunotherapy of malignant melanoma: results of a randomized trial in patients with lymph node metastases’, in W. D. Terry and S. A. Rosenberg (eds), Immunotherapy of Human Cancer, Elsevier North Holland, New York, Amsterdam, Oxford, 1982, pp. 245– 249. 14 Pinsky, C. M., Hirshaut, Y., Wanebo, H. J., Hilal, E. Y., Fortner, J. G., Miké, V., Schottenfeld, D. and Oettgen, H. F. ‘ Surgical adjuvant immunotherapy with BCG in patients with malignant melanoma: results of a prospective, randomized trial’, in W. D. Terry and D. Windhorst (eds), Immunotherapy of Cancer: Present Status of Trials in Man, Raven Press, New York, 1978, pp. 27– 33. 15 Pinsky, C. M. and Oettgen, H. F. ‘Surgical adjuvant therapy for malignant melanoma’, Surgical Clinics of North America, 61, 1259– 1266 (1981). 16 Cunningham, T. J., Schoenfeld, D., Nathanson, L., Wolter, J., Patterson, W. B. and Cohen, M. H. ‘ A controlled study of adjuvant therapy in patients with Stage I and II malignant melanoma’, in W. D. Terry and D. Windhorst (eds), Immunotherapy of Cancer: Present Status of Trials in Man, Raven Press, New York, 1978, pp. 19– 25. 17 Beretta, G. ‘ Progress reort of a controlled study of prolonged chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma’, in W. D. Terry and S. A. Rosenberg (eds), Immunotherapy of Human Cancer, Elsevier North Holland, New York, Amsterdam, Oxford, 1982, pp. 259– 260. 18 Gutterman, J. U., Mavligit, G., Gottlieb, J. A., Burgess, M. A., McBride, C. E., Einhorn, L., Freireich, E. J. and Hersh, E. M. ‘Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and Bacillus Calmette-Guerin’, New England Journal of Medicine, 291, 592– 597 (1974). 19 Costanzi, J. J. ‘ Chemotherapy and BCG in the treatment of disseminated malignant melanoma’, in W. D. Terry and D. Windhorst (eds), Immunotherapy of Cancer: Present Status of Trials in Man, Raven Press, New York, 1978, pp. 87– 93. Citing Literature Volume3, Issue4October/December 1984Pages 325-329 ReferencesRelatedInformation